Compare Abeona Therapeutics Inc (ABEO) vs A O Smith Corp (AOS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs A O Smith Corp — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while A O Smith Corp trades at $59.7 (market cap $8.45B). The key difference: A O Smith Corp is far larger — about 22.6× Abeona Therapeutics Inc's market cap, and A O Smith Corp pays a 2.32% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | AOS | |
|---|---|---|
Market Cap | $373.32M | $8.45B |
Sector | Health | Industrials |
52-Week High | $7.23 | $80.47 |
52-Week Low | $4.17 | $55.78 |
Enterprise Value | $228.22M | $8.90B |
Dividend Yield | — | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
A.O. Smith (AOS) trades at $61.31, down 2.25% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported a Q1 2026 earnings miss ($0.85 actual vs. $0.94 expected) but maintains strong profitability with a 13.84% net margin and 28.27% ROE. Recent leadership changes include CEO Stephen Shafer becoming chairman as of July 1, 2026 (PRNewswire, June 22, 2026).
The stock shows mixed signals: solid fundamentals and a $68 consensus price target suggest upside, but recent earnings weakness and repeated Zacks Strong Sell ratings (June 18, 2026) indicate near-term headwinds. Investors face risks from China market softness and competitive pressures, though cash flow stability and dividend payments provide support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About A O Smith Corp
A.O. Smith Corporation manufactures and markets comprehensive lines of residential and commercial gas, gas tankless, and electric water heaters. Supplementary products include water heating equipment, condensing and noncondensing boilers, and water system tanks. The company's two operating segments are by geographic region: North America (majority of total revenue) and the Rest of the World. A material portion of sales in North America derive from replacing existing products, and the company utilizes a wholesale distribution channel and multiple selling locations. The Rest of the World segment sells primarily to Asian countries and operates sales offices to expand distribution and market its product portfolio.
Read more on AOS →
